Collector
Giriş Yap
GSK Agrees to Buy Nuvalent for $10.6 Billion | Collector
GSK Agrees to Buy Nuvalent for $10.6 Billion

GSK Agrees to Buy Nuvalent for $10.6 Billion

GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)

Go to News Site